Market Overview

UPDATE: Canaccord Genuity Raises PT to $115 on Edwards Lifesciences Ahead of Q4 Results

Share:
Related EW
The Zacks Analyst Blog Highlights: Huntington Ingalls Industries, Raytheon, Lockheed Martin, General Dynamics and Textron
Defense Stock Roundup: LMT-Tata Group Tie Up for F-16, HII, GD, RTN Get Big Deals from Pentagon
Fed, FANGs, Autos, Defense, Eateries On Deck: Investing Action Plan (Investor's Business Daily)

Canaccord Genuity reiterated its Buy rating on Edwards Lifesciences (NYSE: EW) and raised the price target from $109.00 to $115.00.

Canaccord Genuity noted, "We expect strong sequential US sales growth in Q4 (44%E), driven by TF TAVI uptake in Cohort B patients and initial uptake in Cohort A-high risk patients. While we expect tepid growth in Europe (4% Y/Y) - reflecting austerity measures, pricing pressure, and new competitive valves – we think Q4 results will show meaningful improvement from the weak Q3, as we think registry data in H2/12 boded well for SAPIEN vs. CoreValve and also think EW's share of transaortic market (TAo) improved."

Edwards Lifesciences closed at $93.41 on Friday.

Latest Ratings for EW

DateFirmActionFromTo
Jul 2017Morgan StanleyMaintainsOverweight
May 2017Goldman SachsInitiates Coverage OnBuy
Feb 2017BTIG ResearchDowngradesBuyNeutral

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!